![Mike Zaworotko group on X: "Cocrystals here there and everywhere - part 2 Cocrystals are a major research theme @SSPCentre EMA + FDA green light pharmaceutical cocrystals as active drug substances; generic Mike Zaworotko group on X: "Cocrystals here there and everywhere - part 2 Cocrystals are a major research theme @SSPCentre EMA + FDA green light pharmaceutical cocrystals as active drug substances; generic](https://pbs.twimg.com/media/FATpL4nXIAAd_1q.jpg)
Mike Zaworotko group on X: "Cocrystals here there and everywhere - part 2 Cocrystals are a major research theme @SSPCentre EMA + FDA green light pharmaceutical cocrystals as active drug substances; generic
![Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20180606105214147-0711:S0007125000240397:S0007125000240397_tab4.gif?pub-status=live)
Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core
![Full article: Subgroup analysis of the non-interventional study VIVALDI: Agomelatine in treatment-naïve patients, in combination therapy and after treatment switch Full article: Subgroup analysis of the non-interventional study VIVALDI: Agomelatine in treatment-naïve patients, in combination therapy and after treatment switch](https://www.tandfonline.com/cms/asset/13dea63a-fd11-48f3-ae14-f49f53def26c/ijpc_a_892138_f0003_b.gif)
Full article: Subgroup analysis of the non-interventional study VIVALDI: Agomelatine in treatment-naïve patients, in combination therapy and after treatment switch
![Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics - Miriam Saiz-Rodríguez, Dolores Ochoa, Carmen Belmonte, Manuel Román, Danilo Vieira de Lara, Pablo Zubiaur, Dora Koller, Gina Mejía, Francisco Abad-Santos, 2019 Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics - Miriam Saiz-Rodríguez, Dolores Ochoa, Carmen Belmonte, Manuel Román, Danilo Vieira de Lara, Pablo Zubiaur, Dora Koller, Gina Mejía, Francisco Abad-Santos, 2019](https://journals.sagepub.com/cms/10.1177/0269881119827959/asset/images/large/10.1177_0269881119827959-fig1.jpeg)
Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics - Miriam Saiz-Rodríguez, Dolores Ochoa, Carmen Belmonte, Manuel Román, Danilo Vieira de Lara, Pablo Zubiaur, Dora Koller, Gina Mejía, Francisco Abad-Santos, 2019
![PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale](https://i1.rgstatic.net/publication/281057776_Better_sexual_acceptability_of_agomelatine_25_and_50_mg_compared_to_escitalopram_20_mg_in_healthy_volunteers_A_9-week_placebo-controlled_study_using_the_PRSexDQ_scale/links/565d64cd08aeafc2aac77147/largepreview.png)
PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale
![PDF) Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder PDF) Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder](https://i1.rgstatic.net/publication/353632699_Drug_use_evaluation_A_two-year_retrospective_review_of_the_effectiveness_and_tolerability_of_agomelatine_versus_mirtazapine_in_patients_with_depressive_disorder/links/61073bc10c2bfa282a15acc8/largepreview.png)
PDF) Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder
![PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale](https://i1.rgstatic.net/publication/23267285_Better_sexual_acceptability_of_agomelatine_25_and_50_mg_compared_with_paroxetine_20_mg_in_healthy_male_volunteers_An_8-week_placebo-controlled_study_using_the_PRSEXDQ-SALSEX_scale/links/0fcfd50216cd106508000000/largepreview.png)